Orbeos (Atorvastatin)

Atorvastatin blocks the enzyme HMG‑CoA reductase in the liver, which is essential for cholesterol synthesis. By reducing intracellular cholesterol, the liver increases the number of LDL receptors on its surface, enhancing removal of LDL particles from the bloodstream and lowering plasma cholesterol levels.

The appropriate dose of Orbeos is determined by the prescribing clinician based on the patient’s lipid profile, cardiovascular risk, age, and renal or hepatic function. Dosage may be adjusted over time to achieve target lipid levels while monitoring safety parameters.

Statins, including atorvastatin, are contraindicated in pregnancy because they may cause fetal harm. Women of child‑bearing potential should use effective contraception. Atorvastatin is also not recommended while breastfeeding, as it can pass into breast milk and affect the infant.

To request Orbeos, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Orbeos (atorvastatin) is a high‑potency, long‑acting statin that typically provides greater LDL‑cholesterol reduction at lower doses compared with older agents such as simvastatin or pravastatin. Its pharmacokinetic profile allows once‑daily dosing, and it has a well‑characterized safety record when used as directed.

Orbeos tablets should be stored at room temperature, below 25 °C, in the original container to protect from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Orbeos is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a full glass of water. Patients should follow the dosing schedule prescribed by their healthcare professional.

The most serious adverse events include rhabdomyolysis, severe hepatic injury, and life‑threatening allergic reactions. Patients should promptly report unexplained muscle pain, weakness, dark urine, jaundice, or signs of an allergic response such as rash, swelling, or difficulty breathing.

Orbeos is contraindicated in individuals with active liver disease, unexplained persistent elevations of serum transaminases, known hypersensitivity to atorvastatin or any excipients, and in pregnant or nursing women. Caution is also advised for patients with severe renal impairment or those taking interacting medications.